<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01945944</url>
  </required_header>
  <id_info>
    <org_study_id>08-13-11</org_study_id>
    <nct_id>NCT01945944</nct_id>
  </id_info>
  <brief_title>Nebulized Hypertonic Saline for Mechanically Ventilated Children</brief_title>
  <official_title>Nebulized Hypertonic Saline for Mechanically Ventilated Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children who need to be on a ventilator often have thick secretions/mucus in their lungs.
      These secretions can obstruct the breathing tube and their windpipe, which can worsen lung
      function and prolong the need for the ventilator. Hypertonic saline is a medicine that is
      used to thin out secretions in patients with cystic fibrosis (and other conditions). We
      hypothesize that having children on a ventilator inhale this medication will shorten the
      amount of time that they need to be on the ventilator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent pediatric data shows that less than 80% of children mechanically ventilated for â‰¥ 96
      hours survived to PICU discharge, while 100% of children mechanically ventilated for &lt; 96
      hours survived to PICU discharge. Interventions that decrease duration of mechanical
      ventilation may improve outcome by limiting ventilator-induced lung injury, sedative
      medication usage and ventilator-associated pneumonia. Obstructive airway secretions may
      prolong mechanical ventilation by causing atelectasis and endotracheal tube obstruction, with
      resultant cardio-respiratory instability. Nebulized hypertonic saline (HTS) is used to
      decrease mucus viscosity and increase mucociliary clearance in patients with diseases such as
      cystic fibrosis and bronchiolitis, and has been used to enhance airway clearance in
      mechanically ventilated children. Administering nebulized HTS to mechanically ventilated
      children may facilitate airway clearance and shorten mechanical ventilation.

      In a randomized study of children &lt; 2 years old following cardiac surgery, patients given
      dornase, another mucolytic agent, had a significantly decreased duration of mechanical
      ventilation versus those given saline placebo (52 hrs vs. 82 hrs). HTS may be even more
      effective, as mechanically ventilated newborns with persistent atelectasis had more
      improvement in radiographic findings and oxygen saturation when randomized to receive
      hypertonic saline compared to those randomized to receive dornase. This may be because
      dornase may only be effective in patients with leukocytes or bacterial present in tracheal
      aspirates, while HTS may be effective in all ventilated patients. Further study of the impact
      of prophylactic mucolytic therapy on the duration of mechanical ventilation in children is
      warranted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Mechanical Ventilation</measure>
    <time_frame>typically 4 days - 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atelectasis</measure>
    <time_frame>during mechanical ventilation (typically 4 days - 2 weeks)</time_frame>
    <description>using chest x ray score. The score measures the amount of lung collapse (&quot;atelectasis&quot;) observed on a chest x-ray. For each of the 5 lung lobes, 1 point is given for linear atelectasis, 2 points for sub-segmental atelectasis and 3 points for lobar atelectasis. The range is 0-15 points, with higher scores reflecting more severe lung collapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wheezing</measure>
    <time_frame>during mechanical ventilation (typically 4 days - 2 weeks)</time_frame>
    <description>as dichotomous outcome (yes/no) following drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>during hospitalization (typically 4 days - 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>during hospitalization (typically 4 days - 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Sodium From Baseline</measure>
    <time_frame>during hospitalization (typically 4 days - 2 weeks)</time_frame>
    <description>The baseline sodium was the last level measured prior to study initiation, typically within 24hrs of study initiation. The change in blood sodium level was calculated as the difference between the mean post-enrollment sodium level during ICU care and the sodium level at enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic Compliance</measure>
    <time_frame>during mechanical ventilation (typically 4 days - 2 weeks)</time_frame>
    <description>measured in ml/cm H20/kg using parameters on mechanical ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation</measure>
    <time_frame>during mechanical ventilation (typically 4 days - 2 weeks)</time_frame>
    <description>SaO2/FiO2. This is a measure of how will the lungs are providing oxygen to the body. Higher ratios reflect better lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dead Space</measure>
    <time_frame>during mechanical ventilation (typically 4 days - 2 weeks)</time_frame>
    <description>in % of tidal volume, using parameters on mechanical ventilator. Dead space is a measure of how much of the lung is not able to move air into and out of the body. Higher levels of dead space reflect higher levels of lung dysfunction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertonic Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypertonic saline (3%), 3mL every 6hrs for up to 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic saline (3%)</intervention_name>
    <description>3mL of HTS given via nebulizer every 6hrs</description>
    <arm_group_label>Hypertonic Saline</arm_group_label>
    <other_name>3% saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (0.9% saline)</intervention_name>
    <description>3mL of normal saline given via nebulizer every 6hrs</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  invasive mechanical ventilation of &lt; 12 hrs duration prior to enrollment

          -  expected duration of mechanical ventilation of &gt; 48hrs from enrollment

          -  age &lt; 18yo

        Exclusion Criteria:

          -  inclusion in another clinical study

          -  cystic fibrosis

          -  status asthmaticus

          -  pulmonary hemorrhage/contusion

          -  home O2 use

          -  home non-invasive positive pressure (CPAP/BiPAP) ventilation use

          -  pre-existing tracheostomy

          -  prescription of mucolytic medication by primary clinical team

          -  allergy to inhaled saline/hypertonic saline or albuterol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven L Shein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital (of Univ. Hospitals Case Med. Center)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Payen V, Jouvet P, Lacroix J, Ducruet T, Gauvin F. Risk factors associated with increased length of mechanical ventilation in children. Pediatr Crit Care Med. 2012 Mar;13(2):152-7. doi: 10.1097/PCC.0b013e3182257a24.</citation>
    <PMID>21760567</PMID>
  </reference>
  <reference>
    <citation>Riethmueller J, Borth-Bruhns T, Kumpf M, Vonthein R, Wiskirchen J, Stern M, Hofbeck M, Baden W. Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children. Pediatr Pulmonol. 2006 Jan;41(1):61-6. Erratum in: Pediatr Pulmonol. 2006 Apr;41(4):388.</citation>
    <PMID>16265663</PMID>
  </reference>
  <reference>
    <citation>Dilmen U, Karagol BS, Oguz SS. Nebulized hypertonic saline and recombinant human DNase in the treatment of pulmonary atelectasis in newborns. Pediatr Int. 2011 Jun;53(3):328-31. doi: 10.1111/j.1442-200X.2010.03245.x.</citation>
    <PMID>20831650</PMID>
  </reference>
  <reference>
    <citation>Prodhan P, Greenberg B, Bhutta AT, Hyde C, Vankatesan A, Imamura M, Jaquiss RD, Dyamenahalli U. Recombinant human deoxyribonuclease improves atelectasis in mechanically ventilated children with cardiac disease. Congenit Heart Dis. 2009 May-Jun;4(3):166-73. doi: 10.1111/j.1747-0803.2009.00289.x.</citation>
    <PMID>19489944</PMID>
  </reference>
  <reference>
    <citation>Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006458. doi: 10.1002/14651858.CD006458.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;7:CD006458.</citation>
    <PMID>18843717</PMID>
  </reference>
  <reference>
    <citation>Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, McNamara S, Johnson R, Kronmal R, Davis SD; ISIS Study Group. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA. 2012 Jun 6;307(21):2269-77. doi: 10.1001/jama.2012.5214.</citation>
    <PMID>22610452</PMID>
  </reference>
  <reference>
    <citation>Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006 Jan 19;354(3):229-40.</citation>
    <PMID>16421364</PMID>
  </reference>
  <reference>
    <citation>Altunhan H, AnnagÃ¼r A, Pekcan S, Ors R, KoÃ§ H. Comparing the efficacy of nebulizer recombinant human DNase and hypertonic saline as monotherapy and combined treatment in the treatment of persistent atelectasis in mechanically ventilated newborns. Pediatr Int. 2012 Feb;54(1):131-6. doi: 10.1111/j.1442-200X.2011.03519.x.</citation>
    <PMID>22114907</PMID>
  </reference>
  <reference>
    <citation>Youness HA, Mathews K, Elya MK, Kinasewitz GT, Keddissi JI. Dornase alpha compared to hypertonic saline for lung atelectasis in critically ill patients. J Aerosol Med Pulm Drug Deliv. 2012 Dec;25(6):342-8. doi: 10.1089/jamp.2011.0954. Epub 2012 Mar 13.</citation>
    <PMID>22413805</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2013</study_first_submitted>
  <study_first_submitted_qc>September 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2013</study_first_posted>
  <results_first_submitted>July 27, 2015</results_first_submitted>
  <results_first_submitted_qc>May 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 28, 2016</results_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Steven Shein</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>mucolytic</keyword>
  <keyword>respiratory failure</keyword>
  <keyword>atelectasis</keyword>
  <keyword>hypertonic saline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
Placebo (0.9% saline)</description>
        </group>
        <group group_id="P2">
          <title>Hypertonic Saline</title>
          <description>Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
Hypertonic saline (3%)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
Placebo (0.9% saline)</description>
        </group>
        <group group_id="B2">
          <title>Hypertonic Saline</title>
          <description>Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
Hypertonic saline (3%)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" lower_limit="3.1" upper_limit="174.2"/>
                    <measurement group_id="B2" value="12.7" lower_limit="5.6" upper_limit="32.6"/>
                    <measurement group_id="B3" value="17.9" lower_limit="5.1" upper_limit="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PEEP (positive end-expiratory pressure)</title>
          <units>cm-H20</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="5" upper_limit="6"/>
                    <measurement group_id="B2" value="7" lower_limit="6.5" upper_limit="8"/>
                    <measurement group_id="B3" value="6" lower_limit="5" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Mechanical Ventilation</title>
        <time_frame>typically 4 days - 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
Placebo (0.9% saline)</description>
          </group>
          <group group_id="O2">
            <title>Hypertonic Saline</title>
            <description>Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
Hypertonic saline (3%)</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Mechanical Ventilation</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.5" lower_limit="74.4" upper_limit="146.1"/>
                    <measurement group_id="O2" value="208.1" lower_limit="136.3" upper_limit="319.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atelectasis</title>
        <description>using chest x ray score. The score measures the amount of lung collapse (&quot;atelectasis&quot;) observed on a chest x-ray. For each of the 5 lung lobes, 1 point is given for linear atelectasis, 2 points for sub-segmental atelectasis and 3 points for lobar atelectasis. The range is 0-15 points, with higher scores reflecting more severe lung collapse.</description>
        <time_frame>during mechanical ventilation (typically 4 days - 2 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
Placebo (0.9% saline): 3mL of normal saline given via nebulizer every 6hrs</description>
          </group>
          <group group_id="O2">
            <title>Hypertonic Saline</title>
            <description>Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
Hypertonic saline (3%): 3mL of HTS given via nebulizer every 6hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Atelectasis</title>
          <description>using chest x ray score. The score measures the amount of lung collapse (&quot;atelectasis&quot;) observed on a chest x-ray. For each of the 5 lung lobes, 1 point is given for linear atelectasis, 2 points for sub-segmental atelectasis and 3 points for lobar atelectasis. The range is 0-15 points, with higher scores reflecting more severe lung collapse.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" lower_limit="3.92" upper_limit="6"/>
                    <measurement group_id="O2" value="4" lower_limit="2.33" upper_limit="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wheezing</title>
        <description>as dichotomous outcome (yes/no) following drug administration</description>
        <time_frame>during mechanical ventilation (typically 4 days - 2 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
Placebo (0.9% saline): 3mL of normal saline given via nebulizer every 6hrs</description>
          </group>
          <group group_id="O2">
            <title>Hypertonic Saline</title>
            <description>Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
Hypertonic saline (3%): 3mL of HTS given via nebulizer every 6hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Wheezing</title>
          <description>as dichotomous outcome (yes/no) following drug administration</description>
          <units>percentage of drug doses w/ wheezing</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Length of Stay</title>
        <time_frame>during hospitalization (typically 4 days - 2 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
Placebo (0.9% saline): 3mL of normal saline given via nebulizer every 6hrs</description>
          </group>
          <group group_id="O2">
            <title>Hypertonic Saline</title>
            <description>Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
Hypertonic saline (3%): 3mL of HTS given via nebulizer every 6hrs</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Length of Stay</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="12.5"/>
                    <measurement group_id="O2" value="12" lower_limit="9" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <time_frame>during hospitalization (typically 4 days - 2 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
Placebo (0.9% saline): 3mL of normal saline given via nebulizer every 6hrs</description>
          </group>
          <group group_id="O2">
            <title>Hypertonic Saline</title>
            <description>Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
Hypertonic saline (3%): 3mL of HTS given via nebulizer every 6hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="9" upper_limit="22.5"/>
                    <measurement group_id="O2" value="17" lower_limit="16" upper_limit="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Sodium From Baseline</title>
        <description>The baseline sodium was the last level measured prior to study initiation, typically within 24hrs of study initiation. The change in blood sodium level was calculated as the difference between the mean post-enrollment sodium level during ICU care and the sodium level at enrollment.</description>
        <time_frame>during hospitalization (typically 4 days - 2 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
Placebo (0.9% saline): 3mL of normal saline given via nebulizer every 6hrs</description>
          </group>
          <group group_id="O2">
            <title>Hypertonic Saline</title>
            <description>Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
Hypertonic saline (3%): 3mL of HTS given via nebulizer every 6hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Sodium From Baseline</title>
          <description>The baseline sodium was the last level measured prior to study initiation, typically within 24hrs of study initiation. The change in blood sodium level was calculated as the difference between the mean post-enrollment sodium level during ICU care and the sodium level at enrollment.</description>
          <units>mEq/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="-0.9" upper_limit="6.7"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-4.1" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dynamic Compliance</title>
        <description>measured in ml/cm H20/kg using parameters on mechanical ventilator</description>
        <time_frame>during mechanical ventilation (typically 4 days - 2 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
Placebo (0.9% saline): 3mL of normal saline given via nebulizer every 6hrs</description>
          </group>
          <group group_id="O2">
            <title>Hypertonic Saline</title>
            <description>Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
Hypertonic saline (3%): 3mL of HTS given via nebulizer every 6hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Dynamic Compliance</title>
          <description>measured in ml/cm H20/kg using parameters on mechanical ventilator</description>
          <units>mL/kg/cm-H20</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.52" lower_limit="4.21" upper_limit="8.14"/>
                    <measurement group_id="O2" value="4.47" lower_limit="2.94" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygenation</title>
        <description>SaO2/FiO2. This is a measure of how will the lungs are providing oxygen to the body. Higher ratios reflect better lung function.</description>
        <time_frame>during mechanical ventilation (typically 4 days - 2 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
Placebo (0.9% saline): 3mL of normal saline given via nebulizer every 6hrs</description>
          </group>
          <group group_id="O2">
            <title>Hypertonic Saline</title>
            <description>Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
Hypertonic saline (3%): 3mL of HTS given via nebulizer every 6hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygenation</title>
          <description>SaO2/FiO2. This is a measure of how will the lungs are providing oxygen to the body. Higher ratios reflect better lung function.</description>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239" lower_limit="196" upper_limit="280"/>
                    <measurement group_id="O2" value="188" lower_limit="162" upper_limit="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dead Space</title>
        <description>in % of tidal volume, using parameters on mechanical ventilator. Dead space is a measure of how much of the lung is not able to move air into and out of the body. Higher levels of dead space reflect higher levels of lung dysfunction.</description>
        <time_frame>during mechanical ventilation (typically 4 days - 2 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
Placebo (0.9% saline): 3mL of normal saline given via nebulizer every 6hrs</description>
          </group>
          <group group_id="O2">
            <title>Hypertonic Saline</title>
            <description>Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
Hypertonic saline (3%): 3mL of HTS given via nebulizer every 6hrs</description>
          </group>
        </group_list>
        <measure>
          <title>Dead Space</title>
          <description>in % of tidal volume, using parameters on mechanical ventilator. Dead space is a measure of how much of the lung is not able to move air into and out of the body. Higher levels of dead space reflect higher levels of lung dysfunction.</description>
          <units>percentage of lung volume</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="20" upper_limit="37"/>
                    <measurement group_id="O2" value="37" lower_limit="26" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
Placebo (0.9% saline)</description>
        </group>
        <group group_id="E2">
          <title>Hypertonic Saline</title>
          <description>Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
Hypertonic saline (3%)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Desaturation (oxygen)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>As shown above, baseline lung function (as measured by PEEP) was worse in the treatment (HTS) group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Steven Shein, MD</name_or_title>
      <organization>Rainbow Babies and Children's Hospital</organization>
      <phone>216-844-3310</phone>
      <email>drstevenshein@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

